Martin Shkreli

A strong bearish view is presented on the Quantum Computing sector, suggesting investors avoid or consider shorting stocks like IONQ and QBTS due to skepticism about their business models. High-conviction short ideas include ProKidney (PROK), based on fundamental doubts about its core science, and Anavex (AVXL), on the belief its drug is ineffective. Ultragenyx (RARE) faces a near-term bearish outlook after a negative clinical trial update, increasing its risk profile significantly. Conversely, confidence remains high in Nvidia (NVDA), as the immense and ongoing demand for its AI chips supports continued growth. For highly risk-tolerant investors, Kala Bio (KALA) is presented as a speculative "lotto ticket" with the potential for a 10x return if its upcoming trial data is positive.

The quantum computing sector, particularly stocks like IONQ and D-Wave (QBTS), is presented as a high-conviction short opportunity due to a belief that the technology has no viable path to profitability. The speaker is especially bearish on QBTS, predicting its potential failure within the next two quarters because it lacks a marketable product. Other specific short-selling candidates mentioned include biotech firms INmune Bio (INMB) and Vore (VOR). In contrast, Meta Platforms (META) is highlighted as an attractive long-term investment, considered "still cheap" even at its large size. The bullish case for META is driven by its phenomenal and sustained revenue growth, which is expected to continue.

Consider shorting speculative quantum computing stocks like IonQ (IONQ), Quantum Computing Inc. (QUBT), and D-Wave Quantum (QBTS), which are viewed as potential "scams" facing significant downside. Speculative biotech stocks Capricor Therapeutics (CAPR) and Anavex (AVXL) are also identified as strong short candidates based on perceived flawed science and questionable data. A specific short position is held in INmune Bio (INMB) with a target price of $1 to close the position. On the long side, NVIDIA (NVDA) is presented as an extremely bullish opportunity, with a belief it will be the first company to reach a $10 trillion market cap. Finally, Celsius (CELH) is considered a "pretty safe short" due to slowing growth and intense competition.

Consider buying Sarepta Therapeutics (SRPT), as the market may be over-discounting the risk to its key drug, Elevidys, presenting a significant long-term opportunity. For a high-conviction bearish trade, consider shorting Inmune Bio (INMB), which is projected to have significant downside with a potential price target of $0.50. The quantum computing sector, including stocks like QBTS and IONQ, is also presented as a compelling thematic short due to hype outpacing current technology. Investors holding Robinhood (HOOD) should consider taking profits, as the stock appears to be overvalued after its recent run-up. For those with a very high risk tolerance, Cassava Sciences (SAVA) is highlighted as a potential "once in a lifetime" opportunity in the small biotech space.

Consider avoiding or shorting the entire quantum computing sector, including IonQ (IONQ), which is viewed as a high-risk speculation lacking real-world applications and strong institutional support. Sarepta Therapeutics (SRPT) is flagged as a high-conviction bearish idea due to what are described as significant safety issues with its gene therapy products. These specific risks reflect the broader danger in the biotech sector, where many companies have seen their valuations collapse. On the other hand, Robinhood (HOOD) is showing positive momentum and is highlighted as a stock to watch for potential upside. Investors should remain skeptical of over-hyped themes like tokenization and prioritize investments with clear utility over speculative narratives.

The analyst's highest conviction call is to short the quantum computing sector, explicitly naming Quantumscape (QS) as a "great short" due to its perceived lack of fundamental value. Similarly, investors are advised to maintain or initiate short positions on Cassava Sciences (SAVA), as it is grouped with other speculative companies expected to decline. Following a failed Phase 2 trial, ImmuneBio (INMB) is viewed with extreme skepticism and its Alzheimer's drug is considered a failure. The company's plan to seek a partner is interpreted as a major red flag that it is abandoning development. The core thesis is to bet against these speculative biotech and tech stocks, which are seen as fundamentally overvalued.

A strong bearish view is held on InMune Bio (INMB) following the failure of its Phase 2 Alzheimer's drug trial to meet its primary goal. The analyst is short the stock, believing it could fall below $1 per share and that the company's positive spin on subgroup data is misleading. Conversely, Sarepta Therapeutics (SRPT) is presented as a long-term value investment for patient investors. While considered a "good value play," the investment in SRPT is expected to be a "slog" and may take time to materialize. Therefore, SRPT should only be considered as one component within a larger, diversified portfolio.

A highly bearish case is presented for Inmune Therapeutics (INMB) following the complete failure of its Alzheimer's drug trial. The drug failed its primary endpoint, and the company's positive spin on subgroup data is a common tactic with a historically low chance of success. With significant safety issues and a weak financial position, the analysis suggests the stock is a strong sell or short candidate. A price target of $0.50 to $1.00 is proposed for INMB. It is expected that the stock will trade below its cash per share, a common outcome for failed biotech companies.

A high-conviction bearish opportunity is identified in Inmune Bio (INMB), with a prediction that the stock could fall 90% following its upcoming clinical data release. This thesis is based on a recent financing deal where INMB sold shares at a massive discount, signaling management's lack of confidence in their own data. Conversely, Sarepta Therapeutics (SRPT) is presented as a major long-term investment holding due to its recovery potential, despite recent underperformance. Other stocks with a strong bearish outlook include Anavex (AVXL), Capricor (CAPR), and IonQ (IONQ), which are viewed as potential short-selling candidates. For investors seeking stability, Intercontinental Exchange (ICE) is highlighted as a high-quality company with a very profitable business model.

A high-conviction short opportunity is identified in InMune Bio (INMB), with expectations of a 90% stock drop following its upcoming Alzheimer's trial data release. Conversely, Sarepta Therapeutics (SRPT) is a strong long-term buy, with its limb-girdle muscular dystrophy (LGMD) gene therapy pipeline viewed as a major, underappreciated catalyst. The analyst is also actively shorting speculative stocks BigBear.ai (BBAI), IonQ (IONQ), and D-Wave Quantum (QBTS), believing they are fundamentally flawed. For a potential long idea, Madrigal Pharmaceuticals (MDGL) was mentioned favorably and is worth further research. These event-driven biotech trades carry significant risk and investors should proceed with caution.

A high-conviction bearish trade is on InMune Bio (INMB) ahead of its imminent Alzheimer's data, with puts at strikes like $5 or $2.50 being a way to position for an expected trial failure. Amgen (AMGN) is a contrarian buy opportunity, as the market over